Literature DB >> 23700124

Possible overuse of 3-stage procedures for active ulcerative colitis.

Caitlin W Hicks1, Richard A Hodin, Liliana Bordeianou.   

Abstract

IMPORTANCE: There is an assumption that patients treated with 3-stage procedures for active ulcerative colitis are undergoing a safer surgical approach and thus spared the complications associated with a 2-stage procedure. However, there is a paucity of data addressing the validity of this assumption, and the optimal staging approach for patients traditionally considered at high risk for anastomotic leak remains unclear.
OBJECTIVES: To identify factors associated with 3- vs 2-stage procedures and to determine their impact on surgical outcomes.
DESIGN: Retrospective analysis of patients who underwent 2-stage or 3-stage ileal pouch-anal anastomosis (IPAA) surgery for active ulcerative colitis due to failure of medical management over a 10.5-year period (September 1, 2000, to March 30, 2011). The mean (SEM) follow-up was 5.15 (0.24) years (range, 0.26-11.09 years).
SETTING: Single large academic medical center. PATIENTS: One hundred forty-four patients treated with 3- or 2-stage IPAA surgery for active ulcerative colitis. Among these patients, 77 were male and 67 were female. The mean (SEM) age was 34.6 (1.0) years (range, 11-67 years). Of the 144 patients, 116 (80.6%) had a 2-stage procedure and 28 (19.4%) had a 3-stage procedure.
INTERVENTIONS: Two-stage vs 3-stage IPAA procedures for active ulcerative colitis. MAIN OUTCOMES AND MEASURES: Factors leading to decision for 3-stage procedure, postoperative outcomes with 3-stage vs 2-stage procedures, and risks for complications in patients undergoing 3-stage vs 2-stage procedures. RESULTS Of 144 patients, only 19.4% had a 3-stage procedure. Decision to perform a 3-stage vs 2-stage procedure was affected by emergent status (P < .001) and hemodynamic instability (P = .04) but not by age, sex, body mass index, use of steroids, or use of anti-tumor necrosis factor agents. For patients with 2-stage procedures, multivariate regression revealed that the number of perioperative complications was affected by surgeon experience (P = .02) but not by emergent status, use of steroids, or use of anti-tumor necrosis factor agents. Two-stage procedures were associated with more perioperative complications on univariate analysis (P = .05), but multivariate regression suggested that this difference was due to surgeon experience (P = .02) rather than to creation of an IPAA at the first operation (P = .55). Importantly, 2-stage procedures did not change the risk of anastomotic leak when all operations were taken into account (odds ratio = 1.09; P = .94). In the long term (mean [SEM], 5.2 [0.2] years), patients who underwent 2-stage surgery had a lower risk of anal stricture (odds ratio = 8.21; P = .01) and no differences in fistula or abscess formation or in pouch failure. CONCLUSIONS AND RELEVANCE: In patients with active ulcerative colitis, use of steroids and anti-tumor necrosis factor agents alone do not appear to justify the decision to avoid IPAA creation at the first operation provided that it is performed by a high-volume inflammatory bowel disease surgeon.

Entities:  

Mesh:

Year:  2013        PMID: 23700124     DOI: 10.1001/2013.jamasurg.325

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  16 in total

Review 1.  Modified two-stage restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis of observational research.

Authors:  William Yu Luo; Siddharth Singh; Raphael Cuomo; Samuel Eisenstein
Journal:  Int J Colorectal Dis       Date:  2020-07-26       Impact factor: 2.571

Review 2.  Perioperative Considerations in Crohn Disease and Ulcerative Colitis.

Authors:  T Paul Nickerson; Amit Merchea
Journal:  Clin Colon Rectal Surg       Date:  2016-06

Review 3.  Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: A narrative review.

Authors:  Luigi Sofo; Paola Caprino; Franco Sacchetti; Maurizio Bossola
Journal:  World J Gastrointest Surg       Date:  2016-08-27

4.  Total abdominal colectomy vs. restorative total proctocolectomy as the initial approach to medically refractory ulcerative colitis.

Authors:  Jinyu Gu; Luca Stocchi; Jeanie Ashburn; Feza H Remzi
Journal:  Int J Colorectal Dis       Date:  2017-05-22       Impact factor: 2.571

Review 5.  State-of-the-art surgical approaches to the treatment of medically refractory ulcerative colitis.

Authors:  Liliana Bordeianou; Lillias Maguire
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

6.  Transabdominal re-do pouch surgery in pediatric patients for failed ileal pouch anal anastomosis: a case matched study.

Authors:  Erman Aytac; Eren Esen; H Hande Aydinli; Hasan T Kirat; David M Schwartzberg; Feza H Remzi
Journal:  Pediatr Surg Int       Date:  2019-06-05       Impact factor: 1.827

7.  Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis.

Authors:  Grace C Lee; Sarah E Deery; Hiroko Kunitake; Caitlin W Hicks; Adriana G Olariu; Lieba R Savitt; Ashwin N Ananthakrishnan; Rocco Ricciardi; Richard A Hodin; Liliana G Bordeianou
Journal:  Int J Colorectal Dis       Date:  2019-01-04       Impact factor: 2.571

Review 8.  The Role of Temporary Fecal Diversion.

Authors:  Amy L Lightner; John H Pemberton
Journal:  Clin Colon Rectal Surg       Date:  2017-05-22

Review 9.  The Management of the Hospitalized Ulcerative Colitis Patient: the Medical-Surgical Conundrum.

Authors:  Michele Carvello; Joseph Watfah; Marcin Włodarczyk; Antonino Spinelli
Journal:  Curr Gastroenterol Rep       Date:  2020-02-10

10.  Delayed Ileal Pouch Anal Anastomosis Has a Lower 30-Day Adverse Event Rate: Analysis From the National Surgical Quality Improvement Program.

Authors:  Bharati Kochar; Edward L Barnes; Anne F Peery; Katherine S Cools; Joseph Galanko; Mark Koruda; Hans H Herfarth
Journal:  Inflamm Bowel Dis       Date:  2018-07-12       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.